Journal of Pathology and Translational Medicine

Volume 53(4); July 2019

Reviews

PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future: Hyojin Kim, Jin-Haeng Chung; J Pathol Transl Med. 2019;53(4):199-206. Published online May 2, 2019; DOI: https://doi.org/10.4132/jptm.2019.04.24; Correction in: J Pathol Transl Med 2020;54(2):196

16,139 View
641 Download
69 Web of Science
62 Crossref

Blockade of the programmed cell death-1 (PD-1) axis has already been established as an effective treatment of non-small cell lung cancer. Immunohistochemistry (IHC) for programmed death-ligand 1 (PD-L1) protein is the only available biomarker that can guide treatment with immune checkpoint inhibitors in non-small cell lung cancer. Because each PD-1/PD-L1 blockade was approved together with a specific PD-L1 IHC assay used in the clinical trials, pathologists have been challenged with performing various assays with a limited sample. To provide a more unified understanding of this, several cross-validation studies between platforms have been performed and showed consistent results. However, the interchangeability of assays may be limited in practice because of the risk of misclassification of patients for the treatment. Furthermore, several issues, including the temporal and spatial heterogeneity of PD-L1 expression in the tumor, and the potential for cytology specimens to be used as an alternative to tissue samples for PD-L1 testing, have still not been resolved. In the future, one of the main aims of immunotherapy research should be to find a novel predictive biomarker for PD-1 blockade therapy and a way to combine it with PD-L1 IHC and other tests.

Citations

Citations to this article as recorded by

A patient similarity-embedded Bayesian approach to prognostic biomarker inference with application to thoracic cancer immunity
Duo Yu, Meilin Huang, Michael J Kane, Brian P Hobbs
Journal of the Royal Statistical Society Series C: Applied Statistics.2025;[Epub] CrossRef
Programmed Cell Death Ligand 1 (PD-L1) and major Histocompatibility Complex Class I (MHC Class I) Expression Patterns and Their Pathologic Associations in triple-Negative Breast Cancer
Ponkrit Kaewkedsri, Piyapharom Intarawichian, Sirawich Jessadapattarakul, Waritta Kunprom, Supinda Koonmee, Malinee Thanee, Ongart Somintara, Anongporn Wongbuddha, Payia Chadbunchachai, Supajit Nawapun, Chaiwat Aphivatanasiri
Breast Cancer: Targets and Therapy.2025; Volume 17: 123. CrossRef
Exploring immune checkpoint inhibitors: Focus on PD-1/PD-L1 axis and beyond
Durre Aden, Samreen Zaheer, Niti Sureka, Monal Trisal, Jai Kumar Chaurasia, Sufian Zaheer
Pathology - Research and Practice.2025; 269: 155864. CrossRef
Prognostic value of HER2 expression in cervical adenocarcinoma: A retrospective cohort study
Qing Xu, Zhuomin Yin, Yueqi Li, Xiu Zhu, Hanmei Lou, Juan Ni
Oncology Letters.2025; 29(5): 1. CrossRef
PD-1/PD-L1 blockade therapy with atezolizumab: a new paradigm in the treatment of non-small cell lung cancer (NSCLC)
Samaneh Moradi, Pedram Sarikhani, Rafid Jihad Albadr, Waam Mohammed Taher, Mariem Alwan, Mahmood Jasem Jawad, Hiba Mushtaq, Niyousha Vakilzadehian
Discover Oncology.2025;[Epub] CrossRef
Precision Oncology in Lung Cancer Surgery
Patrick Bou-Samra, Sunil Singhal
Surgical Oncology Clinics of North America.2024; 33(2): 311. CrossRef
Expression of PD-L1 clones (22C3 and 28-8) in hepatocellular carcinoma: a tertiary cancer care hospital experience
Kashif Asghar, Shaarif Bashir, Muhammad Hassan, Asim Farooq, Muhammad Abu Bakar, Sundus Bilal, Maryam Hameed, Shafqat Mehmood, Asif Loya
Egyptian Liver Journal.2024;[Epub] CrossRef
Engineering Proteus mirabilis improves antitumor efficacy via enhancing cytotoxic T cell responses
Hong Zhang, Yinlin Luo, Xincheng Zhao, Xiande Liu
Molecular Therapy: Oncology.2024; 32(1): 200770. CrossRef
Unlocking the potential of oncology biomarkers: advancements in clinical theranostics
Ankit Kumar Dubey, Ishnoor Kaur, Reecha Madaan, Shikha Raheja, Rajni Bala, Manoj Garg, Suresh Kumar, Viney Lather, Vineet Mittal, Deepti Pandita, Rohit Gundamaraju, Rajeev K. Singla, Rohit Sharma
Drug Metabolism and Personalized Therapy.2024; 39(1): 5. CrossRef
Exploring histological predictive biomarkers for immune checkpoint inhibitor therapy response in non–small cell lung cancer
Uiju Cho, Soyoung Im, Hyung Soon Park
Journal of Pathology and Translational Medicine.2024; 58(2): 49. CrossRef
Predicting efficacy assessment of combined treatment of radiotherapy and nivolumab for NSCLC patients through virtual clinical trials using QSP modeling
Miriam Schirru, Hamza Charef, Khalil-Elmehdi Ismaili, Frédérique Fenneteau, Didier Zugaj, Pierre-Olivier Tremblay, Fahima Nekka
Journal of Pharmacokinetics and Pharmacodynamics.2024; 51(4): 319. CrossRef
Predictions of PD-L1 Expression Based on CT Imaging Features in Lung Squamous Cell Carcinoma
Seong Hee Yeo, Hyun Jung Yoon, Injoong Kim, Yeo Jin Kim, Young Lee, Yoon Ki Cha, So Hyeon Bak
Journal of the Korean Society of Radiology.2024; 85(2): 394. CrossRef
Assessment of Programmed Cell Death Ligand-1 Expression in Non-small Cell Lung Carcinomas by Immunohistochemistry
Sandeep Mani, Archana Lakshmanan, Annapurneswari Subramanyan
Apollo Medicine.2024; 21(1): 57. CrossRef
The efficacy of immune checkpoint inhibitors on low PD‐L1 cervical cancer: A meta‐analysis
Wutao Chen, Nan Zhang, Zhihong He, Qing Li, You Wang, Weihua Lou, Wen Di
Health Science Reports.2024;[Epub] CrossRef
Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer
Arpeet T. Shah, Isabelle Blanchard, Sukhmani K. Padda, Heather A. Wakelee, Joel W. Neal
Clinical Lung Cancer.2024; 25(6): 550. CrossRef
Optimizing immunofluorescence with high-dynamic-range imaging to enhance PD-L1 expression evaluation for 3D pathology assessment from NSCLC tumor tissue
Hsien-Neng Huang, Chun-Wei Kuo, Yu-Ling Hung, Chia-Hung Yang, Yu-Han Hsieh, Yu-Chieh Lin, Margaret Dah-Tsyr Chang, Yen-Yin Lin, Jen-Chung Ko
Scientific Reports.2024;[Epub] CrossRef
The Role of Programmed Cell Death Ligand 1 Expression in Pituitary Tumours: Lessons from the Current Literature
Mariana Lopes-Pinto, Ema Lacerda-Nobre, Ana Luísa Silva, Francisco Tortosa, Pedro Marques
Neuroendocrinology.2024; 114(8): 709. CrossRef
Real‑world evidence of advanced non‑small cell lung carcinoma treated with an immune checkpoint inhibitor plus chemotherapy
Zihan Xu, Huien Zhang, Guikai Ma, Wenjuan Meng, Junliang Du, Xin Wu, Baohong Yang, Ningning Wang, Yanhong Ding, Qingyun Zhang, Na Li, Xuede Zhang, Guohua Yu, Shuzhen Liu, Zhenhua Li
Oncology Letters.2024;[Epub] CrossRef
Clinical impact of concomitant BIO-three use in advanced or recurrent non-small cell lung cancer treated with immune-checkpoint inhibitor
Hitomi Nakatsukasa, Masaya Takahashi, Masahito Shibano, Yusuke Ishigami, Tomoya Kawaguchi, Yasutaka Nakamura, Hiroyasu Kaneda
International Journal of Clinical Oncology.2024; 29(12): 1840. CrossRef
Special issue “The advance of solid tumor research in China”: FGFR4 alterations predict efficacy of immune checkpoint inhibitors in nonsmall cell lung cancer
Guanghui Gao, Longgang Cui, Fei Zhou, Tao Jiang, Wanying Wang, Shiqi Mao, Fengying Wu, Fangli Jiang, Bei Zhang, Ting Bei, Wenchuan Xie, Cheng Zhang, Hougang Zhang, Chan Gao, Xiaochen Zhao, Yuezong Bai, Caicun Zhou, Shengxiang Ren
International Journal of Cancer.2023; 152(1): 79. CrossRef
Molecular Classification of Extrapulmonary Neuroendocrine Carcinomas With Emphasis on POU2F3-positive Tuft Cell Carcinoma
Jiwon Koh, Haeryoung Kim, Kyung Chul Moon, Cheol Lee, Kyoungbun Lee, Han Suk Ryu, Kyeong Cheon Jung, Yoon Kyung Jeon
American Journal of Surgical Pathology.2023; 47(2): 183. CrossRef
Biomarkers for Predicting Response to Personalized Immunotherapy in Gastric Cancer
Moonsik Kim, Ji Yun Jeong, An Na Seo
Diagnostics.2023; 13(17): 2782. CrossRef
PD-L1 Expression in Pituitary Neuroendocrine Tumors/Pituitary Adenomas
Giulia Cossu, Stefano La Rosa, Jean Philippe Brouland, Nelly Pitteloud, Ethan Harel, Federico Santoni, Maxime Brunner, Roy Thomas Daniel, Mahmoud Messerer
Cancers.2023; 15(18): 4471. CrossRef
Prognostic Significance of Programmed Cell Death Ligand 1 Expression in High-Grade Serous Ovarian Carcinoma: A Systematic Review and Meta-Analysis
Jeongwan Kang, Kang Min Han, Hera Jung, Hyunchul Kim
Diagnostics.2023; 13(20): 3258. CrossRef
A targeted expression panel for classification, gene fusion detection and PD-L1 measurements – Can molecular profiling replace immunohistochemistry in non-small cell lung cancer?
Anita Tranberg Simonsen, Amalie Utke, Johanne Lade-Keller, Lasse Westphal Thomsen, Torben Steiniche, Magnus Stougaard
Experimental and Molecular Pathology.2022; 125: 104749. CrossRef
Program death ligand‐1 immunocytochemistry in lung cancer cytological samples: A systematic review
Swati Satturwar, Ilaria Girolami, Enrico Munari, Francesco Ciompi, Albino Eccher, Liron Pantanowitz
Diagnostic Cytopathology.2022; 50(6): 313. CrossRef
Computer-assisted three-dimensional quantitation of programmed death-ligand 1 in non-small cell lung cancer using tissue clearing technology
Yen-Yu Lin, Lei-Chi Wang, Yu-Han Hsieh, Yu-Ling Hung, Yung-An Chen, Yu-Chieh Lin, Yen-Yin Lin, Teh-Ying Chou
Journal of Translational Medicine.2022;[Epub] CrossRef
Correlation Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Programmed Death-Ligand 1 Expression as Prognostic Markers in Non-Small Cell Lung Cancer
Cristina-Florina Pirlog, Horia Teodor Cotan, Andreea Parosanu, Cristina Orlov Slavu, Ana Maria Popa, Cristian Iaciu, Mihaela Olaru, Alexandru Vlad Oprita, Irina Nita, Cornelia Nitipir
Cureus.2022;[Epub] CrossRef
Expert opinion on NSCLC small specimen biomarker testing — Part 2: Analysis, reporting, and quality assessment
Frédérique Penault-Llorca, Keith M. Kerr, Pilar Garrido, Erik Thunnissen, Elisabeth Dequeker, Nicola Normanno, Simon J. Patton, Jenni Fairley, Joshua Kapp, Daniëlle de Ridder, Aleš Ryška, Holger Moch
Virchows Archiv.2022; 481(3): 351. CrossRef
Novel Inflammasome-Based Risk Score for Predicting Survival and Efficacy to Immunotherapy in Early-Stage Non-Small Cell Lung Cancer
Chih-Cheng Tsao, Hsin-Hung Wu, Ying-Fu Wang, Po-Chien Shen, Wen-Ting Wu, Huang-Yun Chen, Yang-Hong Dai
Biomedicines.2022; 10(7): 1539. CrossRef
Comparative Analysis of Mutation Status and Immune Landscape for Squamous Cell Carcinomas at Different Anatomical sites
Wenqi Ti, Tianhui Wei, Jianbo Wang, Yufeng Cheng
Frontiers in Immunology.2022;[Epub] CrossRef
Pan-cancer analysis of the angiotensin II receptor-associated protein as a prognostic and immunological gene predicting immunotherapy responses in pan-cancer
Kai Hong, Yingjue Zhang, Lingli Yao, Jiabo Zhang, Xianneng Sheng, Lihua Song, Yu Guo, Yangyang Guo
Frontiers in Cell and Developmental Biology.2022;[Epub] CrossRef
Molecular imaging of immune checkpoints in oncology: Current and future applications
Shushan Ge, Tongtong Jia, Jihui Li, Bin Zhang, Shengming Deng, Shibiao Sang
Cancer Letters.2022; 548: 215896. CrossRef
PD-L1 expression and association with genetic background in pheochromocytoma and paraganglioma
Katerina Hadrava Vanova, Ondrej Uher, Leah Meuter, Suman Ghosal, Sara Talvacchio, Mayank Patel, Jiri Neuzil, Karel Pacak
Frontiers in Oncology.2022;[Epub] CrossRef
Case report: Variable response to immunotherapy in ovarian cancer: Our experience within the current state of the art
Nicoletta Provinciali, Marco Greppi, Silvia Pesce, Mariangela Rutigliani, Irene Maria Briata, Tania Buttiron Webber, Marianna Fava, Andrea DeCensi, Emanuela Marcenaro
Frontiers in Immunology.2022;[Epub] CrossRef
PD-L1 Is Preferentially Expressed in PIT-1 Positive Pituitary Neuroendocrine Tumours
John Turchini, Loretta Sioson, Adele Clarkson, Amy Sheen, Anthony J. Gill
Endocrine Pathology.2021; 32(3): 408. CrossRef
Comprehensive tumor molecular profile analysis in clinical practice
Mustafa Özdoğan, Eirini Papadopoulou, Nikolaos Tsoulos, Aikaterini Tsantikidi, Vasiliki-Metaxa Mariatou, Georgios Tsaousis, Evgenia Kapeni, Evgenia Bourkoula, Dimitrios Fotiou, Georgios Kapetsis, Ioannis Boukovinas, Nikolaos Touroutoglou, Athanasios Fassa
BMC Medical Genomics.2021;[Epub] CrossRef
CT-Based Hand-crafted Radiomic Signatures Can Predict PD-L1 Expression Levels in Non-small Cell Lung Cancer: a Two-Center Study
Zekun Jiang, Yinjun Dong, Linke Yang, Yunhong Lv, Shuai Dong, Shuanghu Yuan, Dengwang Li, Liheng Liu
Journal of Digital Imaging.2021; 34(5): 1073. CrossRef
Deep Learning of Histopathological Features for the Prediction of Tumour Molecular Genetics
Pierre Murchan, Cathal Ó’Brien, Shane O’Connell, Ciara S. McNevin, Anne-Marie Baird, Orla Sheils, Pilib Ó Broin, Stephen P. Finn
Diagnostics.2021; 11(8): 1406. CrossRef
Molecular Imaging and the PD-L1 Pathway: From Bench to Clinic
David Leung, Samuel Bonacorsi, Ralph Adam Smith, Wolfgang Weber, Wendy Hayes
Frontiers in Oncology.2021;[Epub] CrossRef
A Comparative Study of Immunotherapy as Second-Line Treatment and beyond in Patients with Advanced Non-Small-Cell Lung Carcinoma
Jerónimo Rafael Rodríguez-Cid, Sonia Carrasco-Cara Chards, Iván Romarico González-Espinoza, Vanessa García-Montes, Julio César Garibay-Díaz, Osvaldo Hernández-Flores, Rodrigo Riera-Sala, Anna Gozalishvili-Boncheva, Jorge Arturo Alatorre-Alexander, Luis Ma
Lung Cancer Management.2021;[Epub] CrossRef
Clinical utility of the C‐reactive protein:albumin ratio in non‐small cell lung cancer patients treated with nivolumab
Taisuke Araki, Kazunari Tateishi, Kei Sonehara, Shuko Hirota, Masamichi Komatsu, Manabu Yamamoto, Shintaro Kanda, Hiroshi Kuraishi, Masayuki Hanaoka, Tomonobu Koizumi
Thoracic Cancer.2021; 12(5): 603. CrossRef
Programmed Cell Death Ligand 1‐Transfected Mouse Bone Marrow Mesenchymal Stem Cells as Targeted Therapy for Rheumatoid Arthritis
Qiong-ying Hu, Yun Yuan, Yu-chen Li, Lu-yao Yang, Xiang-yu Zhou, Da-qian Xiong, Zi-yi Zhao, Hiroshi Tanaka
BioMed Research International.2021;[Epub] CrossRef
PD-L1 testing and clinical management of newly diagnosed metastatic non-small cell lung cancer in Spain: MOREL study
Belen Rubio-Viqueira, Margarita Majem Tarruella, Martín Lázaro, Sergio Vázquez Estévez, Juan Felipe Córdoba-Ortega, Inmaculada Maestu Maiques, Jorge García González, Ana Blasco Cordellat, Javier Valdivia-Bautista, Carmen González Arenas, Jose Miguel Sánch
Lung Cancer Management.2021;[Epub] CrossRef
Can Systems Biology Advance Clinical Precision Oncology?
Andrea Rocca, Boris N. Kholodenko
Cancers.2021; 13(24): 6312. CrossRef
Do we need PD‐L1 as a biomarker for thyroid cytologic and histologic specimens?
Marc P. Pusztaszeri, Massimo Bongiovanni, Fadi Brimo
Cancer Cytopathology.2020; 128(3): 160. CrossRef
Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment
Andrea Botticelli, Pamela Vernocchi, Federico Marini, Andrea Quagliariello, Bruna Cerbelli, Sofia Reddel, Federica Del Chierico, Francesca Di Pietro, Raffaele Giusti, Alberta Tomassini, Ottavia Giampaoli, Alfredo Miccheli, Ilaria Grazia Zizzari, Marianna
Journal of Translational Medicine.2020;[Epub] CrossRef
Immune checkpoint inhibitors in advanced non–small cell lung cancer: A metacentric experience from India
Santosh Kumar, Srujana Joga, Bivas Biswas, Deepak Dabkara, Kuruswamy Thurai Prasad, Navneet Singh, Prabhat Singh Malik, Sachin Khurana, Sandip Ganguly, Valliappan Muthu, Ullas Batra
Current Problems in Cancer.2020; 44(3): 100549. CrossRef
Utility of CT radiomics for prediction of PD‐L1 expression in advanced lung adenocarcinomas
Jiyoung Yoon, Young Joo Suh, Kyunghwa Han, Hyoun Cho, Hye‐Jeong Lee, Jin Hur, Byoung Wook Choi
Thoracic Cancer.2020; 11(4): 993. CrossRef
Immune checkpoint inhibitors of the PD-1/PD-L1-axis in non-small cell lung cancer: promise, controversies and ambiguities in the novel treatment paradigm
Lars H. Breimer, Petros Nousios, Louise Olsson, Hans Brunnström
Scandinavian Journal of Clinical and Laboratory Investigation.2020; 80(5): 360. CrossRef
Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts
Jean-David Fumet, Caroline Truntzer, Mark Yarchoan, Francois Ghiringhelli
European Journal of Cancer.2020; 131: 40. CrossRef
Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient
Giovanni Rossi, Alessandro Russo, Marco Tagliamento, Alessandro Tuzi, Olga Nigro, Giacomo Vallome, Claudio Sini, Massimiliano Grassi, Maria Giovanna Dal Bello, Simona Coco, Luca Longo, Lodovica Zullo, Enrica Teresa Tanda, Chiara Dellepiane, Paolo Pronzato
Cancers.2020; 12(5): 1125. CrossRef
Current status and future perspectives of liquid biopsy in non-small cell lung cancer
Sunhee Chang, Jae Young Hur, Yoon-La Choi, Chang Hun Lee, Wan Seop Kim
Journal of Pathology and Translational Medicine.2020; 54(3): 204. CrossRef
Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record
Fabio Pagni, Umberto Malapelle, Claudio Doglioni, Gabriella Fontanini, Filippo Fraggetta, Paolo Graziano, Antonio Marchetti, Elena Guerini Rocco, Pasquale Pisapia, Elena V. Vigliar, Fiamma Buttitta, Marta Jaconi, Nicola Fusco, Massimo Barberis, Giancarlo
Cancers.2020; 12(7): 1800. CrossRef
PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
Ana Bocanegra, Ester Blanco, Gonzalo Fernandez-Hinojal, Hugo Arasanz, Luisa Chocarro, Miren Zuazo, Pilar Morente, Ruth Vera, David Escors, Grazyna Kochan
International Journal of Molecular Sciences.2020; 21(16): 5918. CrossRef
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer
Danny Rischin, Marta Gil-Martin, Antonio González-Martin, Irene Braña, June Y. Hou, Daniel Cho, Gerald S. Falchook, Silvia Formenti, Salma Jabbour, Kathleen Moore, Aung Naing, Kyriakos P. Papadopoulos, Joaquina Baranda, Wen Fury, Minjie Feng, Elizabeth St
Gynecologic Oncology.2020; 159(2): 322. CrossRef
Atezolizumab: A Review in Extensive-Stage SCLC
James E. Frampton
Drugs.2020; 80(15): 1587. CrossRef
Prognostic and clinicopathological roles of programmed death‐ligand 1 (PD‐L1) expression in thymic epithelial tumors: A meta‐analysis
Hyun Min Koh, Bo Gun Jang, Hyun Ju Lee, Chang Lim Hyun
Thoracic Cancer.2020; 11(11): 3086. CrossRef
Präzisionsmedizin bei NSCLC im Zeitalter der Immuntherapie: Neue Biomarker zur Selektion der am besten geeigneten Therapie oder des am besten geeigneten Patienten
Giovanni Rossi, Alessandro Russo, Marco Tagliamento, Alessandro Tuzi, Olga Nigro, Giacomo Vollome, Claudio Sini, Massimiliano Grassi, Maria Giovanna Dal Bello, Simona Coco, Luca Longo, Lodovica Zullo, Enrica Teresa Tanda, Chiara Dellepiane, Paolo Pronzato
Kompass Pneumologie.2020; 8(6): 300. CrossRef
Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation
Seung Eun Lee, Yu Jin Kim, Minjung Sung, Mi-Sook Lee, Joungho Han, Hong Kwan Kim, Yoon-La Choi
International Journal of Molecular Sciences.2019; 20(19): 4794. CrossRef
Detailed Characterization of Immune Cell Infiltrate and Expression of Immune Checkpoint Molecules PD-L1/CTLA-4 and MMR Proteins in Testicular Germ Cell Tumors Disclose Novel Disease Biomarkers
João Lobo, Ângelo Rodrigues, Rita Guimarães, Mariana Cantante, Paula Lopes, Joaquina Maurício, Jorge Oliveira, Carmen Jerónimo, Rui Henrique
Cancers.2019; 11(10): 1535. CrossRef
Basis of PD1/PD-L1 Therapies
Barbara Seliger
Journal of Clinical Medicine.2019; 8(12): 2168. CrossRef

How to Foster Professional Values during Pathology Residency: Yong-Jin Kim; J Pathol Transl Med. 2019;53(4):207-209. Published online June 27, 2019; DOI: https://doi.org/10.4132/jptm.2019.06.12

5,319 View
109 Download
2 Web of Science
2 Crossref

Abstract PDF

The importance of professional and ethical behavior by physicians both in training and in practice cannot be overemphasized, particularly in pathology. Professionalism education begins in medical school, and professional attitudes and behaviors are further internalized during residency. Learning how to be a professional is a vital part of residency training. While hospital- or institution-based lecture style educational programs exist, they are often ineffective because the curriculum is not applicable to all specialties, although the basic concepts are the same. In this paper, the author suggests ways for institutions to develop professional attitude assessments and to survey residents’ responses to various unprofessional situations using case scenarios.

Citations

Citations to this article as recorded by

A modified Delphi approach to nurturing professionalism in postgraduate medical education in Singapore
Yao Hao Teo, Tan Ying Peh, Ahmad Bin Hanifah Marican Abdurrahman, Alexia Sze Inn Lee, Min Chiam, Warren Fong, Limin Wijaya, Lalit Kumar Radha Krishna
Singapore Medical Journal.2024; 65(6): 313. CrossRef
A Scoping Review of Professionalism in Neurosurgery
William Mangham, Kara A. Parikh, Mustafa Motiwala, Andrew J. Gienapp, Jordan Roach, Michael Barats, Jock Lillard, Nickalus Khan, Adam Arthur, L. Madison Michael
Neurosurgery.2023;[Epub] CrossRef

Current Status of and Perspectives on Cervical Cancer Screening in Korea: Sung-Chul Lim, Chong Woo Yoo; J Pathol Transl Med. 2019;53(4):210-216. Published online May 16, 2019; DOI: https://doi.org/10.4132/jptm.2019.04.11

9,435 View
269 Download
8 Web of Science
9 Crossref

Abstract PDF

Since the introduction of the Papanicolaou (Pap) smear system in 1943, cervicovaginal cytology has been used as a standard screening test for cervical cancer. The dissemination of this test contributed to reductions of the incidence and mortality of cervical cancer worldwide. In Korea, regular health check-ups for industrial workers and their family members were introduced in 1988 and were performed as part of the National Cancer Screening Program in 1999. As a result, the incidence of cervical cancer in Korea has been steadily decreasing. However, about 800 cases of cervical cancer-related deaths are reported each year due to false-negative test results. Hence, new screening methods have been proposed. Liquid-based cytology (LBC) was introduced in 1996 to overcome the limitations of conventional Pap smears. Since then, other LBC methods have been developed and utilized, including the human papilloma virus test—a method with higher sensitivity that requires fewer screenings. In this study, we review current issues and future perspectives related to cervical cancer screening in Korea.

Citations

Citations to this article as recorded by

A questionnaire study on disparity of cervical cancer prevention programs in Asia‐Oceania
Ka Yu Tse, Kimio Ushijima, Ai Ling Tan, Perapong Intasorn, Jitendra Pariyar, Chih‐Long Chang, Efren J. Domingo, Hiralal Konar, Suresh Kumarasamy, Brahmana Askandar Tjokroprawiro, Sarikapan Wilailak
Journal of Obstetrics and Gynaecology Research.2023; 49(4): 1230. CrossRef
Current state of cytopathology residency training: a Korean national survey of pathologists
Uiju Cho, Tae Jung Kim, Wan Seop Kim, Kyo Young Lee, Hye Kyoung Yoon, Hyun Joo Choi
Journal of Pathology and Translational Medicine.2023; 57(2): 95. CrossRef
Meeting the challenges of cervical cancer screening and HPV vaccination in the UK
Roxanne Westwood, Joanna Lavery
Primary Health Care.2022; 32(01): 22. CrossRef
Local and Metastatic Relapses in a Young Woman with Papillary Squamous Cell Carcinoma of the Uterine Cervix
Ha Young Woo, Hyun-Soo Kim
Diagnostics.2022; 12(3): 599. CrossRef
Serum Human Epididymis Protein 4 as a Prognostic Marker in Cervical Cancer
Woo Yeon Hwang, Dong Hoon Suh, Kidong Kim, Yong Beom Kim, Jae Hong No
Cancer Control.2022;[Epub] CrossRef
HPV detection and/or cytological diagnostics
Sanja Milenković
Glasnik javnog zdravlja.2022; 96(3): 313. CrossRef
Clinical management of abnormal Pap tests: differences between US and Korean guidelines
Seyeon Won, Mi Kyoung Kim, Seok Ju Seong
Journal of Pathology and Translational Medicine.2020; 54(3): 213. CrossRef
Current status of cytopathology practices in Korea: annual report on the Continuous Quality Improvement program of the Korean Society for Cytopathology for 2018
Yosep Chong, Haeyoen Jung, Jung-Soo Pyo, Soon Won Hong, Hoon Kyu Oh
Journal of Pathology and Translational Medicine.2020; 54(4): 318. CrossRef
Cytomorphological Features of Hyperchromatic Crowded Groups in Liquid-Based Cervicovaginal Cytology: A Single Institutional Experience
Youngeun Lee, Cheol Lee, In Ae Park, Hyoung Jin An, Haeryoung Kim
Journal of Pathology and Translational Medicine.2019; 53(6): 393. CrossRef

Original Articles

Association between Expression of 8-OHdG and Cigarette Smoking in Non-small Cell Lung Cancer: Ae Ri An, Kyoung Min Kim, Ho Sung Park, Kyu Yun Jang, Woo Sung Moon, Myoung Jae Kang, Yong Chul Lee, Jong Hun Kim, Han Jung Chae, Myoung Ja Chung; J Pathol Transl Med. 2019;53(4):217-224. Published online March 11, 2019; DOI: https://doi.org/10.4132/jptm.2019.02.20

7,604 View
240 Download
19 Web of Science
19 Crossref

Abstract PDF

Background
Exposure to cigarette smoking (CS) is a major risk factor for the development of lung cancer. CS is known to cause oxidative DNA damage and mutation of tumor-related genes, and these factors are involved in carcinogenesis. 8-Hydroxydeoxyguanosine (8-OHdG) is considered to be a reliable biomarker for oxidative DNA damage. Increased levels of 8-OHdG are associated with a number of pathological conditions, including cancer. There are no reports on the expression of 8-OHdG by immunohistochemistry in non-small cell lung cancer (NSCLC).
Methods
We investigated the expression of 8-OHdG and p53 in 203 NSCLC tissues using immunohistochemistry and correlated it with clinicopathological features including smoking.
Results
The expression of 8-OHdG was observed in 83.3% of NSCLC. It was significantly correlated with a low T category, negative lymph node status, never-smoker, and longer overall survival (p < .05) by univariate analysis. But multivariate analysis revealed that 8-OHdG was not an independent prognostic factor for overall survival in NSCLC patients. The aberrant expression of p53 significantly correlated with smoking, male, squamous cell carcinoma, and Ki-67 positivity (p < .05).
Conclusions
The expression of 8-OHdG was associated with good prognostic factors. It was positively correlated with never-smokers in NSCLC, suggesting that oxidative damage of DNA cannot be explained by smoking alone and may depend on complex control mechanisms.

Citations

Citations to this article as recorded by

Sustainable framework for automated segmentation and prediction of lung cancer in CT image using CapsNet with U-net segmentation
S.R. Vijayakumar, S. Aarthy, D. Deepa, P. Suresh
Biomedical Signal Processing and Control.2025; 99: 106873. CrossRef
Increased pretreatment triglyceride glucose-body mass index associated with poor prognosis in patients with advanced non-small cell lung cancer
Shaoming Guo, Yi Zhao, Yue Jiang, Huaping Ye, Ying Wang
Clinical Nutrition ESPEN.2024; 59: 412. CrossRef
Oxidative Damage and Telomere Length as Markers of Lung Cancer Development among Chronic Obstructive Pulmonary Disease (COPD) Smokers
Elizabeth Córdoba-Lanús, Luis M. Montuenga, Angélica Domínguez-de-Barros, Alexis Oliva, Delia Mayato, Ana Remírez-Sanz, Francisca Gonzalvo, Bartolomé Celli, Javier J. Zulueta, Ciro Casanova
Antioxidants.2024; 13(2): 156. CrossRef
Automated determination of 8-OHdG in cells and tissue via immunofluorescence using a specially created antibody
Tobias Jung, Nicole Findik, Bianca Hartmann, Katja Hanack, Kai Grossmann, Dirk Roggenbuck, Marc Wegmann, René Mantke, Markus Deckert, Tilman Grune
Biotechnology Reports.2024; 42: e00833. CrossRef
Combination treatment of zinc and selenium intervention ameliorated BPA-exposed germ cell damage in SD rats: elucidation of molecular mechanisms
Chittaranjan Sahu, Gopabandhu Jena
Naunyn-Schmiedeberg's Archives of Pharmacology.2024; 397(9): 6685. CrossRef
Interplay of arsenic exposure and cigarette smoking on oxidative DNA damage in healthy males
Sepideh Nemati-Mansour, Mohammad Mosaferi, Javad Babaie, Asghar Mohammadpoorasl, Reza Dehghanzadeh, Leila Nikniaz, Mohammad Miri
Environmental Sciences Europe.2024;[Epub] CrossRef
The role of tissue persistent organic pollutants and genetic polymorphisms in patients with benign and malignant kidney tumors
Rasih Kocagöz, İlgen Onat, Merve Demirbügen Öz, Burak Turna, Banu Sarsık Kumbaracı, Mehmet Nurullah Orman, Halit Sinan Süzen, Hilmi Orhan
Environmental Toxicology and Pharmacology.2024; 110: 104495. CrossRef
Mitochondrial Plasticity and Glucose Metabolic Alterations in Human Cancer under Oxidative Stress—From Viewpoints of Chronic Inflammation and Neutrophil Extracellular Traps (NETs)
Hui-Ting Lee, Chen-Sung Lin, Chao-Yu Liu, Po Chen, Chang-Youh Tsai, Yau-Huei Wei
International Journal of Molecular Sciences.2024; 25(17): 9458. CrossRef
Oxidative DNA Damage and Arterial Hypertension in Light of Current ESC Guidelines
Radka Hazuková, Zdeněk Zadák, Miloslav Pleskot, Petr Zdráhal, Martin Pumprla, Miloš Táborský
International Journal of Molecular Sciences.2024; 25(23): 12557. CrossRef
Significance of 8-OHdG Expression as a Predictor of Survival in Colorectal Cancer
Myunghee Kang, Soyeon Jeong, Sungjin Park, Seungyoon Nam, Jun-Won Chung, Kyoung Oh Kim, Jungsuk An, Jung Ho Kim
Cancers.2023; 15(18): 4613. CrossRef
Serum 8-Hydroxy-2′-deoxyguanosine Predicts Severity and Prognosis of Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Peng Cao, Chen Zhang, Dong-Xu Hua, Meng-Die Li, Bian-Bian Lv, Lin Fu, Hui Zhao
Lung.2022; 200(1): 31. CrossRef
Redox signaling at the crossroads of human health and disease
Jing Zuo, Zhe Zhang, Maochao Luo, Li Zhou, Edouard C. Nice, Wei Zhang, Chuang Wang, Canhua Huang
MedComm.2022;[Epub] CrossRef
Assessment of MDA and 8-OHdG expressions in ovine pulmonary adenocarcinomas by immunohistochemical and immunofluorescence methods
Emin Karakurt, Enver Beytut, Serpil Dağ, Hilmi Nuhoğlu, Ayfer Yıldız, Emre Kurtbaş
Acta Veterinaria Brno.2022; 91(3): 235. CrossRef
Dietary Antioxidants and Lung Cancer Risk in Smokers and Non-Smokers
Naser A. Alsharairi
Healthcare.2022; 10(12): 2501. CrossRef
Targeting oxidative stress in disease: promise and limitations of antioxidant therapy
Henry Jay Forman, Hongqiao Zhang
Nature Reviews Drug Discovery.2021; 20(9): 689. CrossRef
Association between tobacco substance usage and a missense mutation in the tumor suppressor gene P53 in the Saudi Arabian population
Mikhlid H. Almutairi, Bader O. Almutairi, Turki M. Alrubie, Sultan N. Alharbi, Narasimha R. Parine, Abdulwahed F. Alrefaei, Ibrahim Aldeailej, Abdullah Alamri, Abdelhabib Semlali, Alvaro Galli
PLOS ONE.2021; 16(1): e0245133. CrossRef
Measurement of uranium concentrations in urine samples of adult healthy groups in Najaf governorate with estimation of urine concentrations of 8-OHdG compound as biomarker for DNA damage
Samia K. Abbas, Dhuha S. Saleh, Hayder S. Hussain
Journal of Physics: Conference Series.2021; 1879(3): 032097. CrossRef
Common Data Model and Database System Development for the Korea Biobank Network
Soo-Jeong Ko, Wona Choi, Ki-Hoon Kim, Seo-Joon Lee, Haesook Min, Seol-Whan Oh, In Young Choi
Applied Sciences.2021; 11(24): 11825. CrossRef
EVALUATION OF OXIDATIVE STATUS IN PATIENTS WITH CHRONIC PERIODONTITIS AND ADDITIONAL TOBACCO ABUSE: A CROSS-SECTIONAL STUDY
Didem ÖZKAL EMİNOĞLU, Varol ÇANAKÇI
Atatürk Üniversitesi Diş Hekimliği Fakültesi Dergisi.2020; : 1. CrossRef

CpG Island Methylation in Sessile Serrated Adenoma/Polyp of the Colorectum: Implications for Differential Diagnosis of Molecularly High-Risk Lesions among Non-dysplastic Sessile Serrated Adenomas/Polyps: Ji Ae Lee, Hye Eun Park, Seung-Yeon Yoo, Seorin Jeong, Nam-Yun Cho, Gyeong Hoon Kang, Jung Ho Kim; J Pathol Transl Med. 2019;53(4):225-235. Published online March 19, 2019; DOI: https://doi.org/10.4132/jptm.2019.03.12

8,090 View
241 Download
7 Web of Science
6 Crossref

Abstract PDF Supplementary Material

Background
Although colorectal sessile serrated adenomas/polyps (SSA/Ps) with morphologic dysplasia are regarded as definite high-risk premalignant lesions, no reliable grading or risk-stratifying system exists for non-dysplastic SSA/Ps. The accumulation of CpG island methylation is a molecular hallmark of progression of SSA/Ps. Thus, we decided to classify non-dysplastic SSA/Ps into risk subgroups based on the extent of CpG island methylation.
Methods
The CpG island methylator phenotype (CIMP) status of 132 non-dysplastic SSA/Ps was determined using eight CIMP-specific promoter markers. SSA/Ps with CIMP-high and/or MLH1 promoter methylation were regarded as a high-risk subgroup.
Results
Based on the CIMP analysis results, methylation frequency of each CIMP marker suggested a sequential pattern of CpG island methylation during progression of SSA/P, indicating MLH1 as a late-methylated marker. Among the 132 non-dysplastic SSA/Ps, 34 (26%) were determined to be high-risk lesions (33 CIMP-high and 8 MLH1-methylated cases; seven cases overlapped). All 34 high-risk SSA/Ps were located exclusively in the proximal colon (100%, p = .001) and were significantly associated with older age (≥ 50 years, 100%; p = .003) and a larger histologically measured lesion size (> 5 mm, 100%; p = .004). In addition, the high-risk SSA/Ps were characterized by a relatively higher number of typical base-dilated serrated crypts.
Conclusions
Both CIMP-high and MLH1 methylation are late-step molecular events during progression of SSA/Ps and rarely occur in SSA/Ps of young patients. Comprehensive consideration of age (≥ 50), location (proximal colon), and histologic size (> 5 mm) may be important for the prediction of high-risk lesions among non-dysplastic SSA/Ps.

Citations

Citations to this article as recorded by

MLH1 Methylation Status and Microsatellite Instability in Patients with Colorectal Cancer
Manuel Alejandro Rico-Méndez, Miguel Angel Trujillo-Rojas, María de la Luz Ayala-Madrigal, Jesús Arturo Hernández-Sandoval, Anahí González-Mercado, Melva Gutiérrez-Angulo, José Geovanni Romero-Quintana, Jesús Alonso Valenzuela-Pérez, Ruth Ramírez-Ramírez,
Genes.2025; 16(2): 182. CrossRef
Immune microenvironmental heterogeneity according to tumor DNA methylation phenotypes in microsatellite instability-high colorectal cancers
Jung Ho Kim, Jiyun Hong, Ji Ae Lee, Minsun Jung, Eunwoo Choi, Nam-Yun Cho, Gyeong Hoon Kang, Sangwoo Kim
Cancer Immunology, Immunotherapy.2024;[Epub] CrossRef
How to "pick up" colorectal serrated lesions and polyps in daily histopathology practice: From terminologies to diagnostic pitfalls
Thai H Tran, Vinh H Nguyen, Diem TN Vo
World Journal of Clinical Oncology.2024; 15(9): 1157. CrossRef
Serrated Colorectal Lesions: An Up-to-Date Review from Histological Pattern to Molecular Pathogenesis
Martino Mezzapesa, Giuseppe Losurdo, Francesca Celiberto, Salvatore Rizzi, Antonio d’Amati, Domenico Piscitelli, Enzo Ierardi, Alfredo Di Leo
International Journal of Molecular Sciences.2022; 23(8): 4461. CrossRef
NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions
Jung Ho Kim, Jeong Hoon Hong, Yoon‐La Choi, Ji Ae Lee, Mi‐kyoung Seo, Mi‐Sook Lee, Sung Bin An, Min Jung Sung, Nam‐Yun Cho, Sung‐Su Kim, Young Kee Shin, Sangwoo Kim, Gyeong Hoon Kang
The Journal of Pathology.2021; 255(4): 399. CrossRef
Evolving pathologic concepts of serrated lesions of the colorectum
Jung Ho Kim, Gyeong Hoon Kang
Journal of Pathology and Translational Medicine.2020; 54(4): 276. CrossRef

Serous Adenocarcinoma of Fallopian Tubes: Histological and Immunohistochemical Aspects: Natalia Hyriavenko, Mykola Lyndin, Kateryna Sikora, Artem Piddubnyi, Ludmila Karpenko, Olha Kravtsova, Dmytrii Hyriavenko, Olena Diachenko, Vladyslav Sikora, Anatolii Romaniuk; J Pathol Transl Med. 2019;53(4):236-243. Published online April 11, 2019; DOI: https://doi.org/10.4132/jptm.2019.03.21

7,253 View
128 Download
4 Web of Science
5 Crossref

Abstract PDF

Background
Although primary cancer of the fallopian tubes is a relatively rare type of tumor in female reproductive organs, its mortality is quite high. It is important to identify molecular and biological markers of this malignancy that determine its specific phenotype.
Methods
The study was carried out on samples received from 71 female patients with primary cancer of the fallopian tubes. The main molecular and biological properties, including hormone status (estrogen receptor [ER], progesterone receptor [PR]), human epidermal growth factor receptor (HER2)/neu expression, proliferative potential (Ki-67), apoptosis (p53, Bcl-2), and pro-angiogenic (vascular endothelial growth factor) quality of serous tumors were studied in comparison with clinical and morphological characteristics.
Results
ER and PR expression is accompanied by low grade neoplasia, early clinical disease stage, and absence of lymphogenic metastasis (p < .001). HER2/neu expression is not typical for primary cancer of the fallopian tubes. Ki-67 expression is characterized by an inverse correlation with ER and PR (p < .05) and is associated with lymphogenic metastasis (p < .01). p53+ status correlates with high grade malignancy, tumor progression, metastasis, negative ER/PR (p < .001), and negative Bcl-2 status (p < .05). Positive Bcl-2 status is positively correlated with ER and PR expression and low grade malignancy.
Conclusions
Complex morphologic (histological and immunohistochemical) study of postoperative material allows estimation of the degree of malignancy and tumor spread to enable appropriate treatment for each case.

Citations

Citations to this article as recorded by

Rare non-serous fallopian tube cancers: institutional experience and literature review
Dmitrii Sumtsov, Georgyi Sumtsov, Nataliia Hyriavenko, Mykola Lyndin, Kateryna Sikora, Nataliia Kalashnik, Svitlana Smiian, Igor Gladchuk
Wiener Medizinische Wochenschrift.2024; 174(9-10): 199. CrossRef
UŞAQLIQ BORULARININ BİRİNCİLİ XƏRÇƏNGİ: DİAQNOSTİKASI VƏ MÜALİCƏSİNİN NƏTİCƏLƏRİ
D.G. Sumtsov, G.O. Sumtsov, N.I. Hyriavenko, S.A. Smiian, N.V. Kalashnyk, K.O. Sikora, N.M. Rozhkovska, I.Z. Gladchuk
Azerbaijan Medical Journal.2023; (4): 75. CrossRef
FEATURES OF ENDOMETRIUM STRUCTURE IN ALCOHOL-ABUSING HIV-INFECTED INDIVIDUALS
M. Lytvynenko
Inter Collegas.2021; 8(1): 52. CrossRef
Concurrent Clostridial Enteritis and Oviductal Adenocarcinoma with Carcinomatosis in an Adult Alpaca (Vicugna pacos)
Mandy Womble, Megan E. Schreeg, Allison Hoch, Enoch B. de Souza Meira, Derek Foster, Christopher Premanandan, Tatiane T. Negrão Watanabe
Journal of Comparative Pathology.2021; 189: 52. CrossRef
Problems of primary fallopian tube cancer diagnostics during and after surgery
D.G. Sumtsov, I.Z. Gladchuk, G.O. Sumtsov, N.I. Hyriavenko, M.S. Lyndin, V.V. Sikora, V.M. Zaporozhan
REPRODUCTIVE ENDOCRINOLOGY.2021; (59): 66. CrossRef

Prognostic Significance of CD109 Expression in Patients with Ovarian Epithelial Cancer: So Young Kim, Kyung Un Choi, Chungsu Hwang, Hyung Jung Lee, Jung Hee Lee, Dong Hoon Shin, Jee Yeon Kim, Mee Young Sol, Jae Ho Kim, Ki Hyung Kim, Dong Soo Suh, Byung Su Kwon; J Pathol Transl Med. 2019;53(4):244-252. Published online May 2, 2019; DOI: https://doi.org/10.4132/jptm.2019.04.16

7,194 View
126 Download
7 Web of Science
6 Crossref

Abstract PDF

Background
Ovarian epithelial cancer (OEC) is the second-most common gynecologic malignancy. CD109 expression is elevated in human tumor cell lines and carcinomas. A previous study showed that CD109 expression is elevated in human tumor cell lines and CD109 plays a role in cancer progression. Therefore, this study aimed to determine whether CD109 is expressed in OEC and can be useful in predicting the prognosis.
Methods
Immunohistochemical staining for CD109 and reverse transcription-quantitative polymerase chain reaction was performed. Then we compared CD109 expression and chemoresistance, overall survival, and recurrence-free survival of OEC patients. Chemoresistance was evaluated by dividing into good-response group and poor-response group by the time to recurrence after chemotherapy.
Results
CD109 expression was associated with overall survival (p = .020), but not recurrence-free survival (p = .290). CD109 expression was not an independent risk factor for overall survival due to its reliability (hazard ratio, 1.58; p = .160; 95% confidence interval, 0.82 to 3.05), although we found that CD109 positivity was related to chemoresistance. The poor-response group showed higher rates of CD109 expression than the good-response group (93.8% vs 66.7%, p = .047). Also, the CD109 mRNA expression level was 2.88 times higher in the poor-response group as compared to the good-response group (p = .001).
Conclusions
Examining the CD109 expression in patients with OEC may be helpful in predicting survival and chemotherapeutic effect.

Citations

Citations to this article as recorded by

Advances in the Study of CD109 in Tumors
平慧周
Medical Diagnosis.2024; 14(02): 167. CrossRef
Identification of CD109 in the extracellular vesicles derived from ovarian cancer stem-like cells
Ye Eun Kim, Jun Se Kim, Min Joo Shin, Seo Yul Lee, Dae Kyoung Kim, Nam-Kyung Lee, Yang Woo Kwon, Kyung-Un Choi, Dong-Soo Suh, Byoung Soo Kim, Sanghwa Jeong, Jae Ho Kim
BMB Reports.2024; 57(12): 527. CrossRef
CD109 Promotes Drug Resistance in A2780 Ovarian Cancer Cells by Regulating the STAT3-NOTCH1 Signaling Axis
Jun Se Kim, Min Joo Shin, Seo Yul Lee, Dae Kyoung Kim, Kyung-Un Choi, Dong-Soo Suh, Dayea Kim, Jae Ho Kim
International Journal of Molecular Sciences.2023; 24(12): 10306. CrossRef
CD109 facilitates progression and 5-fluorouracil resistance of nasopharyngeal carcinoma
Zhenwei Zhu, Fang Zhou, Cheng Mao
Materials Express.2022; 12(9): 1189. CrossRef
Usefulness of CD109 expression as a prognostic biomarker in patients with cancer
Hyun Min Koh, Hyun Ju Lee, Dong Chul Kim
Medicine.2021; 100(11): e25006. CrossRef
Serum CD109 levels reflect the node metastasis status in head and neck squamous cell carcinoma
Sumitaka Hagiwara, Eiichi Sasaki, Yasuhisa Hasegawa, Hidenori Suzuki, Daisuke Nishikawa, Shintaro Beppu, Hoshino Terada, Michi Sawabe, Masahide Takahashi, Nobuhiro Hanai
Cancer Medicine.2021; 10(4): 1335. CrossRef

Progressive Familial Intrahepatic Cholestasis in Korea: A Clinicopathological Study of Five Patients: Hyo Jeong Kang, Soon Auck Hong, Seak Hee Oh, Kyung Mo Kim, Han-Wook Yoo, Gu-Hwan Kim, Eunsil Yu; J Pathol Transl Med. 2019;53(4):253-260. Published online May 16, 2019; DOI: https://doi.org/10.4132/jptm.2019.05.03

7,660 View
225 Download
6 Web of Science
8 Crossref

Abstract PDF

Background
Progressive familial intrahepatic cholestasis (PFIC) is a heterogeneous group of autosomal recessive liver diseases that present as neonatal cholestasis. Little is known of this disease in Korea.
Methods
The records of five patients histologically diagnosed with PFIC, one with PFIC1 and four with PFIC2, by liver biopsy or transplant were reviewed, and ATP8B1 and ABCB11 mutation status was analyzed by direct DNA sequencing. Clinicopathological characteristics were correlated with genetic mutations.
Results
The first symptom in all patients was jaundice. Histologically, lobular cholestasis with bile plugs was the main finding in all patients, whereas diffuse or periportal cholestasis was identified only in patients with PFIC2. Giant cells and ballooning of hepatocytes were observed in three and three patients with PFIC2, respectively, but not in the patient with PFIC1. Immunostaining showed total loss of bile salt export pump in two patients with PFIC2 and focal loss in two. Lobular and portal based fibrosis were more advanced in PFIC2 than in PFIC1. ATP8B1 and ABCB11 mutations were identified in one PFIC1 and two PFIC2 patients, respectively. One PFIC1 and three PFIC2 patients underwent liver transplantation (LT). At age 7 months, one PFIC2 patient was diagnosed with concurrent hepatocellular carcinoma and infantile hemangioma in an explanted liver. The patient with PFIC1 developed steatohepatitis after LT. One patient showed recurrence of PFIC2 after 10 years and underwent LT.
Conclusions
PFIC is not rare in patients with neonatal cholestasis of unknown origin. Proper clinicopathologic correlation and genetic testing can enable early detection and management.

Citations

Citations to this article as recorded by

Exploring the interplay of Emotional intelligence and stress
Ana-Lucia Blendea, Ioan Gotcă , Teodora-ELena Huțanu , Alin Ciobîcă , Daniela Dumitriu
Bulletin of Integrative Psychiatry.2024; 101(2): 45. CrossRef
Hepatocellular carcinoma associated with progressive intrahepatic familial cholestasis type 2: a case report
João Miguel Pimentel, Susana Nobre, Rui Caetano Oliveira, Ricardo Martins, Maria Augusta Cipriano
Clinical Transplantation and Research.2024; 38(3): 241. CrossRef
Progressive Familial Intrahepatic Cholestasis: A Descriptive Study in a Tertiary Care Center
Fahad I. Alsohaibani, Musthafa C. Peedikayil, Abdulaziz F. Alfadley, Mohamed K. Aboueissa, Faisal A. Abaalkhail, Saleh A. Alqahtani, Dirk Uhlmann
International Journal of Hepatology.2023; 2023: 1. CrossRef
Next-generation sequencing panel test results in pediatric patients with progressive familial intrahepatic cholestasis: a single-center experience
Ali TOPAK
The European Research Journal.2023; 9(6): 1438. CrossRef
Progressive Familial Intrahepatic Cholestasis: A Study in Children From a Liver Transplant Center in India
Sagar Mehta, Karunesh Kumar, Ravi Bhardwaj, Smita Malhotra, Neerav Goyal, Anupam Sibal
Journal of Clinical and Experimental Hepatology.2022; 12(2): 454. CrossRef
Liver transplantation in pediatric patients with progressive familial intrahepatic cholestasis: Single center experience of seven cases
Jung-Man Namgoong, Shin Hwang, Hyunhee Kwon, Suhyeon Ha, Kyung Mo Kim, Seak Hee Oh, Seung-Mo Hong
Annals of Hepato-Biliary-Pancreatic Surgery.2022; 26(1): 69. CrossRef
Liver Transplantation for Pediatric Hepatocellular Carcinoma: A Systematic Review
Christos D. Kakos, Ioannis A. Ziogas, Charikleia D. Demiri, Stepan M. Esagian, Konstantinos P. Economopoulos, Dimitrios Moris, Georgios Tsoulfas, Sophoclis P. Alexopoulos
Cancers.2022; 14(5): 1294. CrossRef
Morphology of transplanted liver in recurrent progressive familial intrahepatic cholestasis type 2
I. M. Iljinsky, N. P. Mozheiko, O. M. Tsirulnikova
Russian Journal of Transplantology and Artificial Organs.2021; 22(4): 192. CrossRef

Case Study

Primary Necrobiotic Xanthogranulomatous Sialadenitis with Submandibular Gland Localization without Skin Involvement: Myunghee Kang, Na Rae Kim, Dong Hae Chung, Jae Yeon Seok, Dong Young Kim; J Pathol Transl Med. 2019;53(4):261-265. Published online January 16, 2019; DOI: https://doi.org/10.4132/jptm.2019.01.08

6,983 View
164 Download
1 Web of Science
5 Crossref

Abstract PDF

Necrobiotic xanthogranulomatous reaction is a multiorgan, non-Langerhans cell histiocytosis with an unknown etiology. Occurrence in the salivary gland is extremely rare. We recently identified a case of necrobiotic xanthogranulomatous sialadenitis in a 73-year-old Korean woman who presented with a painless palpable lesion in the chin. There was no accompanying cutaneous lesion. Partial resection and subsequent wide excision with neck dissection were performed. Pathological examination showed a severe inflammatory lesion that included foamy macrophages centrally admixed with neutrophils, eosinophils, lymphocytes, plasma cells, and scattered giant cells, as well as necrobiosis. During the 12-month postoperative period, no grossly remarkable change in size was noted. Necrobiotic xanthogranulomatous inflammation may be preceded by or combined with hematologic malignancy. Although rare, clinicians and radiologists should be aware that an adhesive necrobiotic xanthogranuloma in the salivary gland may present with a mass-like lesion. Further evaluation for hematologic disease and close follow-up are needed when a pathologic diagnosis is made.

Citations

Citations to this article as recorded by

Five Cases of Xanthogranulomatous Sialadenitis
Satoshi Kiyama, Hiroyuki Iuchi, Kotoko Ito, Kengo Nishimoto, Tsutomu Matsuzaki, Masaru Yamashita
Practica Oto-Rhino-Laryngologica.2022; 115(4): 315. CrossRef
Xanthogranulomatous change in a pleomorphic adenoma: An extremely rare variant/degenerative change. Is it fine needle aspiration induced?
Mukta Pujani, Dipti Sidam, Kanika Singh, Aparna Khandelwal, Khushbu Katarya
Diagnostic Cytopathology.2021;[Epub] CrossRef
A Case of Xanthogranulomatous Sialadenitis with Facial Palsy Mimicking Malignancy
Sang Hyun Kim, Sun Woo Kim, Sang Hyuk Lee
Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2021; 64(6): 422. CrossRef
Xanthogranulomatous Sialadenitis, an Uncommon Reactive Change is Often Associated with Warthin’s Tumor
Lihong Bu, Hui Zhu, Emilian Racila, Sobia Khaja, David Hamlar, Faqian Li
Head and Neck Pathology.2020; 14(2): 525. CrossRef
A Case of Xanthogranulomatous Sialadenitis of the Sublingual Gland:A Review of Literature
Naoya KITAMURA, Seiji OHNO, Tetsuya YAMAMOTO
Journal of Japanese Society of Oral Medicine.2019; 25(1): 20. CrossRef

Case Report

Rectal Invasion by Prostatic Adenocarcinoma That Was Initially Diagnosed in a Rectal Polyp on Colonoscopy: Ghilsuk Yoon, Man-Hoon Han, An Na Seo; J Pathol Transl Med. 2019;53(4):266-269. Published online April 11, 2019; DOI: https://doi.org/10.4132/jptm.2019.03.25

7,215 View
125 Download
9 Web of Science
9 Crossref

Abstract PDF

Despite anatomical proximity, prostatic adenocarcinoma with rectal invasion is extremely rare. We present a case of rectal invasion by prostatic adenocarcinoma that was initially diagnosed from a rectal polyp biopsied on colonoscopy in a 69-year-old Korean man. He presented with dull anal pain and voiding discomfort for several days. Computed tomography revealed either prostatic adenocarcinoma with rectal invasion or rectal adenocarcinoma with prostatic invasion. His tumor marker profile showed normal prostate specific antigen (PSA) level and significantly elevated carcinoembryonic antigen level. Colonoscopy was performed, and a specimen was obtained from a round, 1.5 cm, sessile polyp that was 1.5 cm above the anal verge. Microscopically, glandular tumor structures infiltrated into the rectal mucosa and submucosa. Immunohistochemically, the tumor cells showed alpha-methylacyl-CoA-racemase positivity, PSA positivity, and caudal-related homeobox 2 negativity. The final diagnosis of the rectal polyp was consistent with prostatic adenocarcinoma. Here, we present a rare case that could have been misdiagnosed as rectal adenocarcinoma.

Citations

Citations to this article as recorded by

An Extremely Rare Metastatic Prostate Tumor From Rectal Cancer With Characteristic MRI Findings Due to Necrosis
Sohei Iwagami, Shoji Oura, Haruka Miyai, Naoki Kataoka, Masaya Nishihata
Cureus.2025;[Epub] CrossRef
Prostate cancer invading rectal serosa and anal sphincter treated with definitive radiation therapy: Case report and review of the literature
Mi-Jo Lee
Journal of Cancer Research and Therapeutics.2024; 20(3): 1081. CrossRef
Metastatic Adenocarcinoma of the Prostate Masquerading as a Splenic Flexure Colonic Polyp: A Diagnostic Conundrum
Zakaria W Shkoukani, Alaa Chamsin, Mohamed I Abdulmajed
Cureus.2024;[Epub] CrossRef
An Interesting Case of Prostate Cancer Presenting With Colonic Metastasis
Shawn Keating, Ayesha Imtiaz, Kenneth Nahum, Ankita Prasad, Pramil Cheriyath
Cureus.2023;[Epub] CrossRef
Metastase d’un adenocarcinome prostatique au sein d’un polype colique. À propos d’un cas et revue de la littérature
Guillaume Abitbol, Clémence Barthomeuf, Olivier Varennes, Marine Clement, Sami Hakim, Denis Chatelain
Annales de Pathologie.2023; 43(4): 342. CrossRef
Isolated Rectal Metastases from Locally Advanced Carcinoma Prostate Detected by 18F-PSMA-1007 PET/CT
Shashank Shekhar Singh, Rani Kunti Randhir Singh, Narvesh Kumar, Harshvardhan Atrey
World Journal of Nuclear Medicine.2022; 21(03): 248. CrossRef
Rectal Invasion by Metastatic Prostate Adenocarcinoma
Anshu Wadehra, Samer Alkassis, Aliza Rizwan, Omid Yazdanpanah
Cureus.2021;[Epub] CrossRef
Metastatic Prostate Cancer Presenting as a Rectal Polyp: A Rare Occurrence
Ese Uwagbale, Ifeanyichukwu Onukogu, Vimal Bodiwala, Solomon Agbroko, Niket Sonpal
Cureus.2021;[Epub] CrossRef
Local Staging of Prostate Cancer with Multiparametric MRI
Nandan Keshav, Mark D. Ehrhart, Steven C. Eberhardt, Martha F. Terrazas
Seminars in Roentgenology.2021; 56(4): 366. CrossRef

Brief Case Report

Endocervical Adenocarcinoma In Situ Phenotype with Ovarian Metastasis: Hyun-Soo Kim, Yeon Seung Chung, Moon Sik Kim, Hyang Joo Ryu, Ji Hee Lee; J Pathol Transl Med. 2019;53(4):270-272. Published online December 28, 2018; DOI: https://doi.org/10.4132/jptm.2018.12.17

6,210 View
137 Download
7 Web of Science
6 Crossref

PDF

Citations

Citations to this article as recorded by

Endocervical adenocarcinoma in situ with ovarian metastases
Kate Glennon, Ann Treacy, Tony Geoghegan, Paul Downey, Donal Brennan
International Journal of Gynecological Cancer.2022; 32(4): 566. CrossRef
Concurrent metastatic ovarian adenocarcinoma of endocervical adenocarcinoma in situ: A case report emphasizing pathologic diagnostic key points and clinical progress
In Ok Lee, Yee Jung Kim, Hanna Moon, Jae Eun Chung
Gynecologic Oncology Reports.2021; 36: 100766. CrossRef
Peritoneal HPV‐DNA test in cervical cancer (PIONEER study): A proof of concept
Nicolò Bizzarri, Luigi Pedone Anchora, Paola Cattani, Rosa De Vincenzo, Simona Marchetti, Carmine Conte, Vito Chiantera, Valerio Gallotta, Salvatore Gueli Alletti, Giuseppe Vizzielli, Barbara Costantini, Anna Fagotti, Francesco Fanfani, Giovanni Scambia,
International Journal of Cancer.2021; 148(5): 1197. CrossRef
Cervical stromal involvement by endometrial ‘hyperplasia’: a previously unreported phenomenon with recommendations to report as stage II endometrial carcinoma
Jennifer Taylor, W. Glenn McCluggage
Pathology.2021; 53(5): 568. CrossRef
Pelvic and Ovarian Recurrence of Small HPV-associated Cervical Adenocarcinoma With Transformation to Neuroendocrine Carcinoma
Duaa Abu-Sinn, Jackie Jamison, Matthew Evans, W. Glenn McCluggage
International Journal of Gynecological Pathology.2021; 40(6): 541. CrossRef
Superficially Spreading Endocervical Adenocarcinoma in situ with Multifocal Microscopic Involvement of the Endometrial Surface: A Case Report with Emphasis on the Potential for Misdiagnosis Based on Endometrial Curettage Specimens
Inwoo Hwang, Jiyeon Lee, Kyue-Hee Choi, Jiheun Han, Hyun-Soo Kim
Case Reports in Oncology.2020; 13(3): 1530. CrossRef

First
Prev
Page of 1
Next
Last

Previous issues